Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$78.54

0.35 (0.45%)

18:02
06/12/19
06/12
18:02
06/12/19
18:02

AbbVie says patients show improved RA symptoms in upadacitinib trials

AbbVie announced new results from the Phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily through 48 weeks continue to demonstrate improved signs and symptoms of rheumatoid arthritis, as measured by ACR20/50, and clinical remission based on Disease Activity Score 28 C-Reactive Protein less than2.6. The studies evaluate upadacitinib, an investigational, once-daily JAK1-selective inhibitor, in patients with moderately to severely active rheumatoid arthritis. Additionally, data from an integrated safety analysis across five Phase 3 SELECT clinical trials show that treatment with upadacitinib in patients with moderately to severely active rheumatoid arthritis demonstrates a consistent safety profile. These results are being presented at the European League Against Rheumatism Annual European Congress of Rheumatology, June 12-15, in Madrid. "These data continue to support the potential of upadacitinib to help maintain consistent disease control for patients living with moderately to severely active rheumatoid arthritis," said Professor Ronald van Vollenhoven, M.D., Ph.D., Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands. "While remission is the primary treatment goal, in accordance with the American College of Rheumatology and the European League Against Rheumatism recommendations, a majority of patients do not achieve clinical remission today, despite currently available treatment options."

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 16

    Sep

ABBV AbbVie
$78.54

0.35 (0.45%)

04/28/19
BMOC
04/28/19
UPGRADE
Target $79
BMOC
Market Perform
AbbVie upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Alex Arfaei upgraded AbbVie to Market Perform from Underperform and raised his price target for the shares to $79 from $71. The stock closed Friday up 29c to $79.70. The analyst says his bearish thesis has mostly materialized and that he's now more bullish on Skyrizi and Upa. AbbVie can leverage its rebates to secure superior access in the U.S. and drive "strong" launches, Arfaei tells investors in a research note. He believes after a flat 2019, Skyrizi, Upa, Imbruvica/Venclexta and Orilissa should drive 4%-6% revenue growth during 2020-2022. This should improve sentiment on shares of AbbVie, says the analyst.
05/14/19
LEHM
05/14/19
NO CHANGE
Target $25
LEHM
Overweight
Myovant Sciences selloff overdone after report of relugolix data, says Barclays
Barclays analyst Geoffrey Meacham said he thinks the selloff in shares of Myovant Sciences (MYOV) is overdone after the release of relugolix phase 3 uterine fibroids data. He believes investors are "selling the news" and he still believes relugolix has a comparable profile to AbbVie (ABBV) and Neurocrine's (NBIX) elagolix and will find a place in the market given what he sees as positive data reported this morning, Meacham tells investors. He keeps an Overweight rating and $25 price target on Myovant shares, which are down 26% to $12.67 in early afternoon trading.
05/28/19
GSCO
05/28/19
INITIATION
Target $84
GSCO
Neutral
AbbVie initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started AbbVie with a Neutral rating and $84 price target. The analyst projects sales from the company's marketed cancer portfolio and new immunology drugs to ultimately generate sufficient revenue to offset Humira erosion. However, he does not expect "significant visibility" on the uptake of the new immunology launches until 2020, which he thinks is likely to keep AbbVie shares range bound.
05/28/19
GSCO
05/28/19
DOWNGRADE
Target $60
GSCO
Sell
Goldman sees negative sales growth for Gilead, downgrades shares to Sell
Goldman Sachs analyst Terence Flynn downgraded Gilead Sciences (GILD) to Sell from Neutral and lowered his price target for the shares to $60 from $70. The analyst expects Gilead's sales growth to decelerate saying the Truvada/Atripla loss of exclusivities in Sept ember 2020 represents a $3B headwind. Further, Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition, Flynn tells investors in a research note. As a result, the analyst models annual revenue growth for Gilead through 2022 as negative 5%, which he notes is among the lowest in his coverage universe. Meanwhile, the stock trades at a slight premium to other stocks such as Bristol-Myers (BMY) and AbbVie (ABBV), says Flynn.

TODAY'S FREE FLY STORIES

EVA

Enviva

$29.50

-0.24 (-0.81%)

05:11
06/24/19
06/24
05:11
06/24/19
05:11
Upgrade
Enviva rating change  »

Enviva upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$165.16

-1.8 (-1.08%)

05:10
06/24/19
06/24
05:10
06/24/19
05:10
Hot Stocks
Motorola Solutions awarded tender for supplying POC service to Israel Railways »

Motorola Solutions has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

CNTY

Century Casinos

$9.83

-0.3 (-2.96%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Century Casinos management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

CNCE

Concert Pharmaceuticals

$10.90

-0.165 (-1.49%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Concert Pharmaceuticals management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

ATH

Athene Holding

$42.58

-0.8 (-1.84%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Athene Holding management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

SSTI

ShotSpotter

$44.50

0.19 (0.43%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
ShotSpotter management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

ATH

Athene Holding

$42.58

-0.8 (-1.84%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Athene Holding management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

HUBG

Hub Group

$40.70

-1.25 (-2.98%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Hub Group management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 13

    Nov

SPOT

Spotify

$148.17

-1.57 (-1.05%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Spotify management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

INGN

Inogen

$71.29

-1.37 (-1.89%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 26

    Aug

STXB

Spirit of Texas Bancshares

$22.49

0.07 (0.31%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Spirit of Texas Bancshares management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

INWK

InnerWorkings

$4.17

(0.00%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
InnerWorkings management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

OKTA

Okta

$130.77

-2.63 (-1.97%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Okta management to meet with KeyBanc »

Dinner Meeting with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

STFC

State Auto Financial

$34.64

-0.18 (-0.52%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
State Auto Financial management to meet with Sandler O'Neill »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

ABT

Abbott

$85.04

0.07 (0.08%)

, EVTCY

Evotec

$0.00

(0.00%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
American Society for Microbiology to hold a conference »

ASM Microbe 2019 will be…

ABT

Abbott

$85.04

0.07 (0.08%)

EVTCY

Evotec

$0.00

(0.00%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

TTPH

Tetraphase

$0.63

-0.02 (-3.10%)

PRTK

Paratek Pharmaceuticals

$3.77

(0.00%)

TMO

Thermo Fisher

$294.45

1.06 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 02

    Dec

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
JPMorgan U.S. energy team to hold an analyst/industry conference call »

U.S. Energy Analyst…

SCS

Steelcase

$15.46

-0.32 (-2.03%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Steelcase management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 26

    Jun

  • 10

    Jul

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

CLF

Cleveland-Cliffs

$10.04

-0.21 (-2.05%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Cleveland-Cliffs management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

ENS

EnerSys

$65.77

0.4003 (0.61%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
EnerSys management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

GES

Guess

$14.88

0.27 (1.85%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Guess management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

JWN

Nordstrom

$33.43

0.22 (0.66%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Nordstrom management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

NEE

NextEra Energy

$207.69

1.28 (0.62%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
NextEra Energy management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.